Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer

Trial Profile

NeoPHOEBE: Pi3k Inhibition in Her2 OverExpressing Breast cancEr: A Phase II, Randomized, Parallel Cohort, Two Stage, Double-blind, Placebo-controlled Study of Neoadjuvant Trastuzumab Versus Trastuzumab + BKM120 in Combination With Weekly Paclitaxel in HER2-positive, PIK3CA Wild-type and PIK3CA Mutant Primary Breast Cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Feb 2019

At a glance

  • Drugs Buparlisib (Primary) ; Paclitaxel; Trastuzumab
  • Indications Early breast cancer
  • Focus Therapeutic Use
  • Acronyms NeoPHOEBE
  • Sponsors Novare Pharmaceuticals
  • Most Recent Events

    • 04 Feb 2019 Austria, Belgium, Brazil, France, Italy, New Zealand, Peru, Switzerland, Taiwan, United Kingdom were planned locations according European Clinical Trials Database.
    • 31 Aug 2018 Biomarkers information updated
    • 15 Sep 2017 Primary endpoint has not been met. (Pathological complete response (pCR) rate) as per results published in the European Journal of Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top